Tasigna (Nilotinib HCl) Patent Expiration, LOE Window & CMS Spending

Tasigna (Nilotinib HCl) by Novartis: FDA Orange Book core substance LOE 2032-10-07, 6 AB generics, $521.2M 2024 CMS Part D & Medicaid spend, and 12 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorNovartis
FDA Application & PathwayN022068 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2032-10-07
Last Listed Patent or Exclusivity Date2032-10-07
Orange Book Patents (*PED Extensions)12 patents (6 *PED)
Active AB-Rated Generic Competitors6
2024 CMS Total Public Spend$521.2M
2024 Medicare Part D Spend$427.0M
2024 Medicaid Spend$94.2M
Reported Wholesale Price Change (CA SB 17)12 WAC filings (max 27.3% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Novartis across sibling Meru public-data platforms.